 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
This is critical stage for SYBD. All three SYBD products (Fluorovent™, Oxycyte™, and the glucose biosensor) are scheduled to be begin clinical trials during 1999. This is when most "developmental stage" biotechs listed on NASDAQ move to the $5 to $10 level. Once Phase II and Phase III clinical trials are underway, such companies often trade in $10 to $30 range (CLTR is a good example of this). As SYBD receives patent for glucose biosensor and begins clinical trials for all three of its products, it could soon be trading near $1 and higher. A recent example of this is CELN which traded in the $0.25 range and moved quickly to $2 upon announcement of U.S. patents and definitive plans for clinical trials. There is currently no thread for SYBD in the under-$5.00 category. Please post information relevant to SYBD's development and movement into the clinical trials phase here for the benefit of all current and potential shareholders. Best regards, Micro-Selector SYBD Web site: sybd.com *** CORPORATE PROFILE AS LISTED ON WEB SITE *** SYNTHETIC BLOOD INTERNATIONAL, INC. (SYBD) is a biomedical product development company. Building on technology pioneered by Dr. Leland Clark, one of the twentieth century's most innovative and prolific researchers and inventors, SYBD's mission is to commercialize products from our perfluorocarbon and biosensor technology platforms as rapidly as possible. The three products currently under development are Fluorovent™, Oxycyte™, and an implanted glucose sensor. These products will compete in multibillion dollar markets. We intend to exploit fully our technology platforms for additional product opportunities in the biomedical, commercial, and industrial markets. Operating largely as a virtual company, we intend to form partnerships as early as possible with global and/or regional pharmaceutical and medical device companies for product development funding, commercial-scale manufacturing, and maximum global market penetration for our products. In markets where SYBD may not be the first company to obtain regulatory approval, our strategy will be to gain market share based on superior products with significant competitive advantages. Mindful always that SYBD is a publicly held company, our primary long-term goal is to maximize share value and shareholders' return on investment. | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |